Sugi Predict

Sugi Predict / Compounds / SCHEMBL349552

SCHEMBL349552

SCHEMBL349552

O=C(O)C1(c2ccc(Cl)nc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAPRT Q6XQN6 1/20 0.47
▸ AKR1C3 P42330 3/20 0.43
▸ AKR1C2 P52895 3/20 0.43
▸ AKR1C1 Q04828 2/20 0.43
▸ MAP4K4 O95819 2/20 0.42
▸ APP P05067 2/20 0.41
▸ CYP3A4 P08684 2/20 0.41
▸ CYP2C9 P11712 2/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ PSEN1 P49768 1/20 0.41
▸ PSEN2 P49810 1/20 0.41
▸ APH1B Q8WW43 1/20 0.41
▸ NCSTN Q92542 1/20 0.41
▸ APH1A Q96BI3 1/20 0.41
▸ PSENEN Q9NZ42 1/20 0.41
▸ KMT2A Q03164 2/20 0.40
▸ TET3 O43151 1/20 0.40
▸ FBXL19 Q6PCT2 1/20 0.40
▸ CXXC5 Q7LFL8 1/20 0.40
▸ KDM2B Q8NHM5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31247665 1.00 NAPRT (0.47) NAPRTAKR1C3AKR1C2AKR1C1MAP4K4
SCHEMBL17796645 0.93 AKR1C1 (0.53) NAPRTAKR1C3AKR1C2AKR1C1MAP4K4
SCHEMBL9966332 0.93 AKR1C1 (0.49) NAPRTAKR1C3AKR1C2AKR1C1MAP4K4
SCHEMBL29886401 0.93 AKR1C1 (0.53) NAPRTAKR1C3AKR1C2AKR1C1MAP4K4
SCHEMBL23559804 0.89 NAPRT (0.41) NAPRTAKR1C3AKR1C2AKR1C1MAP4K4
SCHEMBL9966329 0.89 MAP4K4 (0.52) NAPRTAKR1C3AKR1C2AKR1C1MAP4K4
SCHEMBL20972073 0.85 NAPRT (0.43) NAPRTAKR1C3MAP4K4KCNQ3KCNQ2
SCHEMBL30636509 0.85 NAPRT (0.43) NAPRTAKR1C3MAP4K4KCNQ3KCNQ2
SCHEMBL3679512 0.84 NAPRT (0.42) NAPRTIDO1PRKAB2PRKAG1PRKAA2
SCHEMBL9966553 0.81 IDO1 (0.44) NAPRTMAP4K4KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719394-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2026-04-08 — — EP disclosed
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE ATOMWISE INC (US) 2026-02-19 — — US disclosed
US-12358904-B2 Inhibitors of TYK2 Atomwise Inc. (US) 2025-07-15 — — US disclosed
US-20240417396-A1 INHIBITORS OF TYK2 Atomwise Inc. 2024-12-19 — — US disclosed
WO-2024250010-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2024-12-05 — — WO disclosed
WO-2022268066-A1 PROTEIN DEGRADATION AGENT 苏州开拓药业股份有限公司 2022-12-29 — — WO disclosed
US-9957229-B2 Amido compounds and their use as pharmaceuticals INCYTE HOLDINGS CORPORATION (US) 2018-05-01 — — US disclosed
US-20170334847-A1 Amido Compounds And Their Use As Pharmaceuticals INCYTE CORPORATION 2017-11-23 — — US disclosed
US-9670154-B2 Amido compounds and their use as pharmaceuticals INCYTE HOLDINGS CORPORATION (US) 2017-06-06 — — US disclosed
EP-1694647-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK CANADA INC (CA) 2016-11-09 — — EP disclosed
US-20080039457-A1 TRIAZOLOTRIAZINES AS KINASE INHIBITORS INCYTE CORPORATION (US) 2008-02-14 — — US disclosed
US-7304081-B2 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION (US) 2007-12-04 — — US disclosed
US-20070179142-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-08-02 — — US disclosed
CN-101001842-A Amido compounds and their use as pharmaceuticals INCYTE CORP (US) 2007-07-18 — — CN disclosed
US-20070099893-A1 Cathepsin cysteine protease inhibitors MERCK CANADA INC. (CA) 2007-05-03 — — US disclosed
EP-1756063-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-02-28 — — EP disclosed
EP-1694647-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Frosst Canada Ltd. (CA) 2006-08-30 — — EP disclosed
US-20050282858-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-22 — — US disclosed
WO-2005110992-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2005-11-24 — — WO disclosed
WO-2005056529-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK FROSST CANADA LTD. (CA) 2005-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039457-A1 TRIAZOLOTRIAZINES AS KINASE INHIBITORS MET, ERBB2, RET NAPRT 4360/4885AKR1C3 3867/4885AKR1C2 4006/4885
US-20170334847-A1 Amido Compounds And Their Use As Pharmaceuticals HSD11B1, CYP11B1, HSD11B2 NAPRT 1990/4885AKR1C3 43/4885AKR1C2 31/4885
US-20240417396-A1 INHIBITORS OF TYK2 TYK2, LCK, JAK2 NAPRT 2630/4885AKR1C3 4669/4885AKR1C2 4372/4885
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE TYK2, FRK, DYRK2 NAPRT 4105/4885AKR1C3 1749/4885AKR1C2 2270/4885
US-12358904-B2 Inhibitors of TYK2 TYK2, LCK, JAK2 NAPRT 2630/4885AKR1C3 4669/4885AKR1C2 4372/4885
US-20070099893-A1 Cathepsin cysteine protease inhibitors CTSB, CTSS, CTSZ NAPRT 3414/4885AKR1C3 2461/4885AKR1C2 2718/4885
US-20050282858-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 NAPRT 1990/4885AKR1C3 43/4885AKR1C2 31/4885
US-20070179142-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 NAPRT 1990/4885AKR1C3 43/4885AKR1C2 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.